-By Warner Todd Huston
If anyone wants a current example of what is looming ahead for medical science at the hands of Obamacare, the Avastin controversy is a perfect one. The Food and Drug Administration (FDA) wants to de-list the cancer drug Avastin one reason being that it is a drug too expensive for government to fund. It is scary to think that the federal government can summarily dismiss cancer drugs merely because of expense, but that is what happens when government starts counting the beans. It becomes an issue of cost instead of effectiveness.
There were other reasons that the FDA wants to dump Avastin, but cost was one of them. One of those that sat in judgment of Avastin admitted that cost was a factor in the decision to delegitimize the treatment. Natalie Compagni Portis, a member of one of the panels that the FDA convened to investigate the drug, said, “We aren’t supposed to talk about cost, but that’s another issue.”
Continue reading “
Feds Deciding When Healthcare Science Costs Too Much To Save Lives”